MyFinsight
Home
Blog
About
Contact
Download
Download image
Net proceeds from
issuance of shares in 2024...
$18,059,379
Net proceeds from
issuance of shares in...
$7,411,554
Net proceeds from
the exercise of...
$3,218,552
Net proceeds from
the exercise of...
$250,260
Cash provided by
financing activities
$28,447,766
Effect of exchange rate
changes
$474,032
Canceled cashflow
$491,979
Net increase
(decrease) in cash, cash...
$10,456,366
Canceled cashflow
$18,465,432
Payments of offering
costs (note 14)
$395,478
Payments of current
portion of long-term...
$96,501
Stock-based compensation
expense
$1,803,195
Other non-cash items
-$804,938
Depreciation and
amortization
$94,046
Cash used in
operating activities
-$18,465,432
Canceled cashflow
$2,702,179
Long term deposit and
other noncurrent...
-$2,852
Net loss
-$20,161,099
Total changes in
operating assets and...
$1,006,512
Canceled cashflow
$2,852
Accounts payable and
other current...
-$468,606
Deferred grant income
-$328,071
Defined benefit pension
plan
-$130,568
Prepaid expenses and
other current assets
$82,119
Back
Back
Cash Flow
source: myfinsight.com
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX)